Please login to the form below

Not currently logged in
Email:
Password:

AZ and Teva reach agreement over Entocort

AZ has reach an agreement with Teva Pharmaceuticals USA to settle patent litigation relating to Entocort EC

AstraZeneca (AZ) has entered into an agreement with generic drug maker, Teva Pharmaceuticals USA (Teva), to settle patent litigation regarding Teva's proposed generic version of AZ's Entocort EC (budesonide) capsules, which lose patent protection as a treatment for adults with Crohn's disease in July 2014, and as a treatment for children in January 2015.

The terms of the settlement agreement give Teva a licence to enter the US market with its generic version of oral budesonide in February 2012, subject to regulatory approval, or earlier in certain circumstances. Teva has conceded that both patents-in-suit in Teva's US Entocort patent litigation are valid and enforceable, and that both Entocort patents-in-suit would be infringed by the manufacture or sale of Teva's generic version of oral budesonide.

The US District Court for the District of Delaware will enter a Consent Judgment and the corresponding patent litigation will be dismissed. Further terms of the settlement remain confidential.

19th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics